Harnessing the Power of Nature's Designs™
About Us
Adjuvia Therapeutics was founded in 2023 by Dr. Laura Hix Glickman, John Carberry and Tim Wilson with the goal of creating novel therapeutics to address rare and chronic diseases that arise from mitochondrial and cellular dysfunction. Our mission is to improve the lives of patients with high unmet medical needs by developing safe and effective orally administered therapies. Our team of dedicated professionals is driven by a shared passion for improving healthcare outcomes, and we are proud to be at the forefront of medical innovation.
Our Science
Adjuvia’s lead compound, ATI-103, is a proprietary formulation of astaxanthin, a powerful antioxidant that has the unique ability to insert into the mitochondrial membrane to protect cells from oxidative stress that is generated during mitochondrial energy production and can be toxically overproduced due to inherited mitochondrial mutations. In addition to its potent antioxidant activities, ATI-103 has the ability to regulate many cell signaling pathways important for metabolic and immune homeostasis. Dysregulation and damage to these pathways can lead to cell death, organ dysfunction and degenerative diseases.
Adjuvia has a patented process to extract the small molecule astaxanthin from natural sources into a proprietary nanoparticle formulation that enables maximum bioavailability and cellular activity following oral delivery.
ATI-103 is currently in IND-enabling studies with the first clinical indication targeting rare mitochondrial genetic diseases, including Friedreich’s Ataxia and Leigh Syndrome.
